Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: GregorioAllegri who wrote (2933)	11/3/2013 6:40:25 PM
From: jq1234si	1 Recommendation Recommended By DewDiligence_on_SI Read Replies (1) \| Respond to of 4474

That's not what I said at all. Quite to the contrary, I believe FDA's numbers which are quite consistent with FDA's original review that is public info. If you had read the review, you would have found the reviewers' explanations how they got all data. They were concerned about hypertension which was not reported fully by trial investigators, but showed up in vital signs measurement data throughout trial. They highlighted that other ABL-BCR inhibitors didn't have similar hypertension profile as ponatinib whose profile was consistent with other VEGF inhibitors. I have posted a lot on this safety issue at iHUB ever since it was approved: siliconinvestor.com By the way, just remember ARIA never disputed FDA reviewers' numbers at all.